ARKG ARK Genomic Revolution ETF

ETF on NYSE (US) · Actively managed · Listing

Daily holdings file Nov 18, 2026 Published at assets.ark-funds.com
Book $1.82B 34 positions
Line items 34
In top 10 59%
Largest holding: Tempus AI, Inc. ($175M) 9.6%
Portfolio date Nov 18, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Tempus AI, Inc., 2.76M shares ($175M).

Tempus AI, Inc.: 9.6% Twist Bioscience Corporation: 8.5% 10x Genomics, Inc.: 7.7% CRISPR Therapeutics AG: 5.2% Guardant Health, Inc.: 5.1% Eli Lilly and Company: 5.0% Illumina, Inc.: 4.7% Absci Corporation: 4.5% Natera, Inc.: 4.5% CareDx, Inc.: 3.7% The other 24 positions: 41.4% $1.82B Holdings value
Current positions Top 10 % of book
Tempus AI, Inc. TEM $175M 9.6%
Twist Bioscience Corporation TWST $155M 8.5%
10x Genomics, Inc. TXG $140M 7.7%
CRISPR Therapeutics AG CRSP $95.4M 5.2%
Guardant Health, Inc. GH $93.4M 5.1%
Eli Lilly and Company LLY $91.6M 5.0%
Illumina, Inc. ILMN $85.0M 4.7%
Absci Corporation ABSI $82.5M 4.5%
Natera, Inc. NTRA $81.5M 4.5%
CareDx, Inc. CDNA $67.6M 3.7%

Slices are % of holdings value.

Healthcare: 98.6% Technology: 1.1% Unclassified: 0.3% 2 sectors
Sectors % of holdings value
Healthcare 98.6%
Technology 1.1%
Unclassified 0.3%
Biotechnology: 49.4% Diagnostics & Research: 26.1% Health Information Services: 9.6% Medical Devices: 8.5% Drug Manufacturers - General: 5.0% Scientific & Technical Instruments: 1.1% Unclassified: 0.3% 6 industries
Industries % of holdings value
Biotechnology 49.4%
Diagnostics & Research 26.1%
Health Information Services 9.6%
Medical Devices 8.5%
Drug Manufacturers - General 5.0%
Scientific & Technical Instruments 1.1%
Unclassified 0.3%

Source: the fund's own published holdings, the portfolio of Nov 18, 2026 (assets.ark-funds.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The ARK Genomic Revolution ETF's ("Fund") investment objective is long-term growth of capital.

Principal investment strategies

The Fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Fund's investment theme of the genomics* revolution ("Genomics Revolution Companies"), which is described below: • Genomic Revolution Companies. Companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing,** analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics,*** molecular medicine and agricultural biotechnology. In selecting companies that the Adviser believes are relevant to a particular investment theme, the Adviser seeks to identify, using its own internal research and analysis, companies capitalizing on disruptive innovation or that are enabling the further development of a theme in the markets in which they operate. The Adviser's internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment themes and identify and take advantage of trends that have ramifications for individual companies or entire industries. The Adviser's process for identifying Genomic Revolution Companies uses both "top down" (thematic research sizing the potential total available market, and surfacing the prime beneficiaries) and "bottom up" (valuation, fundamental and quantitative measures) approaches. In both the Adviser's "top down" and "bottom up" approaches, the Adviser evaluates environmental, social, and governance ("ESG") considerations. In its "top down" approach, the Adviser uses the framework of the United Nations Sustainable Development Goals to integrate ESG considerations into its research and investment process. The Adviser, however, does not use ESG considerations to limit, restrict or otherwise exclude companies or sectors from the Fund's investment universe. In its "bottom up" approach, the Adviser makes its investment decisions primarily based on its analysis of the potential of individual companies, while integrating ESG considerations into that process. The Adviser's highest-conviction investment ideas are those that it believes present the best risk-reward opportunities. The Fund may invest in certain companies that the Adviser believes are well-positioned to capitalize on and expected to devote substantial efforts to business lines enabled by disruptive genomic innovation, even if such companies do not currently derive a substantial portion of their revenues from genomics related activities. Under normal circumstances, substantially all of the Fund's assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Fund's investments will include micro-, small-, medium- and large-capitalization companies. The Fund's investments in foreign equity securities will be in both developed and emerging markets. _______________ * The Adviser defines "genomics" as the study of genes and their functions, and related techniques (e.g., genomic sequencing).

Management and Contact

Adviser
ARK Investment Management LLC
Portfolio managers

The following individual has been primarily responsible for the day-to-day management of the Fund's portfolio since the inception of the Fund: Catherine D. Wood.

Phone
855-406-1506

Track Record as of Dec 31, 2024

1 Year 5 Years 10 Years
Returns Before Taxes -28.09% -6.52% 1.90%
Returns After Taxes on Distributions(1) -28.09% -6.60% 1.62%
Returns After Taxes on Distributions and Sale of Fund Shares(1) -16.63% -4.72% 1.46%
MSCI World Index (reflects no deduction for fees, expenses or taxes) 18.67% 11.17% 9.95%
NASDAQ Healthcare Index (reflects no deduction for fees, expenses or taxes) -0.86% 1.06% 3.19%
S&P 500 Index (reflects no deduction for fees, expenses or taxes) 25.02% 14.53% 13.10%

Holdings as of Nov 18, 2026

34 lines, 33 linked, weights sum to 99.99% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
TEMPUS AI INC-CL A TEM 88023B103 Equity 2,761,952 −39,975 9.63% $ 175.191M
TWIST BIOSCIENCE CORP TWST 90184D100 Equity 1,381,558 +11,337 8.50% $ 154.734M
10X GENOMICS INC-CLASS A TXG 88025U109 Equity 2,480,914 −145,124 7.68% $ 139.675M
CRISPR THERAPEUTICS AG CRSP H17182108 Equity 2,376,723 0 5.24% $ 95.425M
GUARDANT HEALTH INC GH 40131M109 Equity 651,785 −9,425 5.13% $ 93.388M
ELI LILLY & CO LLY 532457108 Equity 64,741 −936 5.04% $ 91.644M
ILLUMINA INC ILMN 452327109 Equity 419,496 −6,071 4.67% $ 84.994M
ABSCI CORP ABSI 00091E109 Equity 10,883,235 −157,547 4.53% $ 82.495M
NATERA INC NTRA 632307104 Equity 283,446 −4,095 4.48% $ 81.482M
CAREDX INC CDNA 14167L103 Equity 906,349 −13,117 3.71% $ 67.577M
BEAM THERAPEUTICS INC BEAM 07373V105 Equity 3,173,277 −45,929 3.60% $ 65.528M
SCHRODINGER INC SDGR 80810D103 Equity 2,429,434 −35,165 3.43% $ 62.339M
ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 Equity 1,974,865 −28,587 3.09% $ 56.264M
COMPASS PATHWAYS PLC CMPS 20451W101 Equity 5,902,847 −85,449 2.59% $ 47.105M
VERACYTE INC VCYT 92337F107 Equity 1,853,663 −26,832 2.47% $ 44.914M
RECURSION PHARMACEUTICALS-A RXRX 75629V104 Equity 16,490,709 −238,719 2.46% $ 44.855M
NURIX THERAPEUTICS INC NRIX 67080M103 Equity 2,790,715 −40,391 2.18% $ 39.74M
PRIME MEDICINE INC PRME 74168J101 Equity 10,107,354 −146,315 2.13% $ 38.812M
ALAMAR BIOSCIENCES INC ALMR 010911105 Equity 1,207,894 −17,485 2.03% $ 37.01M
INTELLIA THERAPEUTICS INC NTLA 45826J105 Equity 3,497,291 0 1.88% $ 34.204M
BUTTERFLY NETWORK INC BFLY 124155102 Equity 5,308,710 −76,843 1.68% $ 30.525M
GENEDX HOLDINGS CORP WGS 81663L200 Equity 622,315 −9,009 1.62% $ 29.429M
IONIS PHARMACEUTICALS INC IONS 462222100 Equity 943,418 −13,650 1.40% $ 25.435M
ARCTURUS THERAPEUTICS HOLDIN ARCT UQ 03969T109 Equity 3,174,891 −45,955 1.39% $ 25.304M
SCRIBE THERAPEUTICS INC SCTX 811033109 Equity 1,597,118 −2,771 1.38% $ 25.187M
IAMBIC THERAPEUTICS INC IAM 45076A101 Equity 1,748,162 −25,298 1.37% $ 24.859M
PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 Equity 12,542,409 0 1.25% $ 22.827M
908 DEVICES INC MASS 65443P102 Equity 2,120,183 −30,693 1.09% $ 19.909M
FREENOME INC FRNM 35661P100 Equity 1,851,391 −26,793 1.00% $ 18.181M
GENERATE BIOMEDICINES INC GENB 370920100 Equity 1,700,605 −24,609 0.92% $ 16.734M
CERUS CORP CERS 157085101 Equity 8,308,352 0 0.87% $ 15.786M
KYMERA THERAPEUTICS INC KYMR 501575104 Equity 127,214 −1,833 0.85% $ 15.459M
QUANTUM-SI INC QSI 74765K105 Equity 7,523,110 −108,901 0.42% $ 7.598M
GOLDMAN FS TRSY OBLIG INST 468
X9USDGSFT Money market 5,057,760 +3,086,623 0.28% $ 5.058M

Trades Nov 17, 2026 to Nov 18, 2026

Holding Ticker Action Before After Change Value
10X GENOMICS INC-CLASS A TXG Sold 2,626,038 2,480,914 −145,124 $ -8.17M
TEMPUS AI INC-CL A TEM Sold 2,801,927 2,761,952 −39,975 $ -2.536M
GUARDANT HEALTH INC GH Sold 661,210 651,785 −9,425 $ -1.35M
ELI LILLY & CO LLY Sold 65,677 64,741 −936 $ -1.325M
TWIST BIOSCIENCE CORP TWST Bought 1,370,221 1,381,558 +11,337 $ 1.27M
ILLUMINA INC ILMN Sold 425,567 419,496 −6,071 $ -1.23M
ABSCI CORP ABSI Sold 11,040,782 10,883,235 −157,547 $ -1.194M
NATERA INC NTRA Sold 287,541 283,446 −4,095 $ -1.177M
CAREDX INC CDNA Sold 919,466 906,349 −13,117 $ -978.004K
BEAM THERAPEUTICS INC BEAM Sold 3,219,206 3,173,277 −45,929 $ -948.434K
SCHRODINGER INC SDGR Sold 2,464,599 2,429,434 −35,165 $ -902.334K
ADAPTIVE BIOTECHNOLOGIES ADPT Sold 2,003,452 1,974,865 −28,587 $ -814.444K
COMPASS PATHWAYS PLC CMPS Sold 5,988,296 5,902,847 −85,449 $ -681.883K
VERACYTE INC VCYT Sold 1,880,495 1,853,663 −26,832 $ -650.139K
RECURSION PHARMACEUTICALS-A RXRX Sold 16,729,428 16,490,709 −238,719 $ -649.316K
NURIX THERAPEUTICS INC NRIX Sold 2,831,106 2,790,715 −40,391 $ -575.168K
PRIME MEDICINE INC PRME Sold 10,253,669 10,107,354 −146,315 $ -561.85K
ALAMAR BIOSCIENCES INC ALMR Sold 1,225,379 1,207,894 −17,485 $ -535.74K
BUTTERFLY NETWORK INC BFLY Sold 5,385,553 5,308,710 −76,843 $ -441.847K
GENEDX HOLDINGS CORP WGS Sold 631,324 622,315 −9,009 $ -426.036K
IONIS PHARMACEUTICALS INC IONS Sold 957,068 943,418 −13,650 $ -368.004K
ARCTURUS THERAPEUTICS HOLDIN ARCT UQ Sold 3,220,846 3,174,891 −45,955 $ -366.261K
IAMBIC THERAPEUTICS INC IAM Sold 1,773,460 1,748,162 −25,298 $ -359.738K
908 DEVICES INC MASS Sold 2,150,876 2,120,183 −30,693 $ -288.207K
FREENOME INC FRNM Sold 1,878,184 1,851,391 −26,793 $ -263.107K
GENERATE BIOMEDICINES INC GENB Sold 1,725,214 1,700,605 −24,609 $ -242.153K
KYMERA THERAPEUTICS INC KYMR Sold 129,047 127,214 −1,833 $ -222.746K
QUANTUM-SI INC QSI Sold 7,632,011 7,523,110 −108,901 $ -109.99K
SCRIBE THERAPEUTICS INC SCTX Sold 1,599,889 1,597,118 −2,771 $ -43.699K

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up